Senti Biosciences authorizes $2 million senior secured convertible note issuance to NSG BioInnovation Fund

• Senti Biosciences amended its securities purchase agreement to allow additional tranches of Midco Senior Secured Convertible Notes.
• Authorized a third-tranche issuance of $2 million aggregate principal of the notes to NSG BioInnovation Fund.
• Closing is expected within three business days of Sept. 1, 2026, subject to customary closing conditions.
• NSG’s purchase is set to satisfy Celadon Partners SPV 35’s remaining obligation to purchase notes under the merger agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-060124), on September 02, 2026, and is solely responsible for the information contained therein.